These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1055 related items for PubMed ID: 31018157

  • 21. Medications Approved for Preventing Migraine Headaches.
    Spindler BL, Ryan M.
    Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
    [Abstract] [Full Text] [Related]

  • 22. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y, Huang ZL.
    Medicine (Baltimore); 2022 Jun 17; 101(24):e29361. PubMed ID: 35713436
    [Abstract] [Full Text] [Related]

  • 23. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
    Cohen F, Yuan H, DePoy EMG, Silberstein SD.
    Neurotherapeutics; 2022 Apr 17; 19(3):922-930. PubMed ID: 35426060
    [Abstract] [Full Text] [Related]

  • 24. [Novel migraine treatment with CGRP-related monoclonal antibodies].
    Shibata M.
    Rinsho Shinkeigaku; 2020 Oct 24; 60(10):668-676. PubMed ID: 32893246
    [Abstract] [Full Text] [Related]

  • 25. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L.
    Headache; 2018 May 24; 58 Suppl 1():33-47. PubMed ID: 29697153
    [Abstract] [Full Text] [Related]

  • 26. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB.
    Neurology; 2020 May 19; 94(20):e2121-e2125. PubMed ID: 31932515
    [Abstract] [Full Text] [Related]

  • 27. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
    Suzuki K, Suzuki S, Fujita H, Sakuramoto H, Shioda M, Hirata K.
    Neuropsychopharmacol Rep; 2024 Jun 19; 44(2):482-484. PubMed ID: 38602109
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 19; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events.
    González-Hernández A, Marichal-Cancino BA, Villalón CM.
    Expert Opin Drug Metab Toxicol; 2021 Oct 19; 17(10):1223-1235. PubMed ID: 34535065
    [Abstract] [Full Text] [Related]

  • 33. Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine.
    Cho S, Kim BK.
    Curr Pain Headache Rep; 2024 Aug 19; 28(8):743-751. PubMed ID: 38683278
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Are antimigraine drugs that influence CGRP levels justified?
    Piechal A, Domitrz I, Kurkowska-Jastrzębska I, Mirowska-Guzel D.
    Pharmacol Rep; 2019 Aug 19; 71(4):624-635. PubMed ID: 31181379
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
    Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.
    BioDrugs; 2017 Dec 19; 31(6):487-501. PubMed ID: 29116598
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.